Genmab A/S ADS (GMAB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Genmab A/S ADS (GMAB) is Neutral.

The composite score behind that read is +0.18, weighing +0.20 of bullish evidence against -0.15 bearish.

Genmab A/S ADS last closed at $37.07, +2.83% on the session.

Against the IVW growth benchmark the position is +2.03% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 47%.

Genmab A/S ADS has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Genmab A/S ADS in the 31st percentile on valuation and the 70th percentile on return on equity, where 100 is best.

Genmab A/S ADS is classified under Health Care / Biotechnology, with a market capitalisation of $22.15B.

StockMap tracks Genmab A/S ADS as the 16th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Genmab A/S ADS ranks 21st of 381 in the group, against a group median of -0.08.